Biogen Idec, Inc. (BIIB) Misses Q2 EPS by 1c, Sales Beat; Guides FY11
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $200.15 +1.50%
EPS Growth %: -41.3%
Financial Fact:
Basic earnings per share attributable to Biogen Idec Inc.: 218.9M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -41.3%
Financial Fact:
Basic earnings per share attributable to Biogen Idec Inc.: 218.9M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $1.36, $0.01 worse than the analyst estimate of $1.37. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.18 billion.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Nike updates Q4 fiscal 2026 outlook with tariff refund benefit
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
